But just because a company does not have crippling debt doesnt mean its a buy. Keith Speights for Without NeoCart, that burn likely comes down. Pricing likely would be favorable, given the lack of alternative treatments. 10 stocks we like better than Ocugen, Inc.When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. There's still a chance that the vaccine could receive a green light in Canada. That pathway will likely require the company to conduct further clinical testing of the vaccine in the U.S. Are there any other near-term catalysts for the biotech stock? Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. As of this writing, Vince Martin has no positions in any securities mentioned. Concerns about the delta variant, the potential need for annual booster shots and the possibility of expanding the vaccines to children have investors hopeful that Covaxin will still eventually be a huge payoff for Ocugen. Typically, I care little about financials with biotechs. Shares of Ocugen ( OCGN -3.10%) fell on Tuesday after an analyst sounded a note of caution to investors. The Motley Fool has no position in any of the stocks mentioned. On its first trading day as OCGN stock, it lost almost 64% of its value and closed that day at $2.85 per share. Biotechnology stocks like Ocugen (NASDAQ:OCGN) are among the markets riskiest plays. Custom BMW. Nor should one look forward to OCGN stock to becoming the next GW Pharmaceuticals (NASDAQ:GWPH) or Cara Therapeutics (NASDAQ:CARA). Even before that point, the most promising candidates generally can find funding. If youre not convinced by now, maybe you will consider OCGN stock a poor investment when looking at the fundamentals. *Stock Advisor returns as of November 20, 2020. 1 Reason to Buy Ocugen in 2023 and 2 Reasons to Sell, 3 Under-the-Radar Stocks With 590% to 772% Upside in 2023, According to Wall Street, 2 Reasons to Avoid a Roth 401(k) for Your Retirement Savings, Warren Buffett's Latest $2.9 Billion Buy Brings His Total Investment in This Stock to $66 Billion in 4 Years, Want $1 Million in Retirement? Create your Watchlist to save your favorite quotes on Nasdaq.com. From a broader perspective, the risk is the same as it is across biotech: most candidates fail. Bharat's offering COVAXIN, a whole-viron inactivated COVID-19 vaccine candidate, has already shown promise in Phase 1 and 2 clinical trials in India and the enrollment of 26,000 subjects for the Phase 3 study is currently underway. Keith Speights owns shares of Pfizer. It peaked at a split-adjusted level of around $778 per share soon after its initial public offering in 2014. Ocugen ( NASDAQ: OCGN) has been one of the more polarizing story stocks of 2021. Just a few days ago, Ocugen (NASDAQ: OCGN) was flying high with shares up more than 460% year to date. This decision isn't surprising, considering that Ocugen previously abandoned the pursuit of an EUA path for the vaccine in adults. Thats not a new problem: a previous Phase 1/2 study, according to the prospectus, was discontinued early due to slow enrollment. The company noted that additional trials may be required as well. It took Moderna roughly 10 months from the initiation of the late-stage study for its COVID-19 vaccine to the point where the company filed for full FDA approval. For priority reviews, the timeline for an approval decision is reduced to six months. But if they do, Ocugen stock at the least looks like an intriguing bet. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. We have provided a few examples below that you can copy and paste to your site: Your image export is now complete. Type a symbol or company name. Ocugen abandoned its pursuit of a U.S. EUA for Covaxin in immunizing adults last year. Type a symbol or company name. Investors were hopeful that the small drugmaker would be able to win U.S. Matthew McCall left Wall Street toactually helpinvestors by getting them into the worlds biggest, most revolutionary trends BEFORE anyone else. The average Ocugen stock price for the last 52 weeks is 2.10. Shares fell 72% on the news, and kept falling after Histogenics decided to suspend development of the product in December 2018. Shares of Ocugen ( OCGN) skyrocketed over 800% in the past three trading sessions after the biopharmaceutical company disclosed it had signed a binding letter of intent (LOI) with India based. Do not expect a recovery in Ocugen stock. The generic form of brimonidine, the active ingredient, is not approved for the condition, according to Ocugens most recent presentation. Investors appear to expect that Bharat's big win for Covaxin in India could translate to success for Ocugen in the U.S. On Dec. 22, Ocugen and Bharat announced a binding letter of intent to jointly develop Covaxin for the U.S. market. From the outside looking inward, it looks like a marriage of two people who got together simply because nobody else would take them. Copyright As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. Copyright 2023 InvestorPlace Media, LLC. Do not expect this to become the biotech who made good like Biogen (NASDAQ:BIIB). Type a symbol or company name. 1125 N. Charles St, Baltimore, MD 21201. UPDATE 1-Soccer-Traore on target as Wolves stun wasteful Spurs, Peruvian communities to resume blockade of crucial "mining corridor", One student loan forgiveness effort 'hasnt gotten the attention it deserves': expert, RPT-Death toll in strike on Ukraine's Zaporizhzhia rises to 11 - officials, Soccer-Traore on target as Wolves stun wasteful Spurs. Still, this stock is cheap for reasons that my colleague Josh Enomoto spelled out well. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. At the beginning of 2020, Ocugen shares were trading at just 47 cents. In that list, you can even include penny-stock trader. From a near-term standpoint, there are two key risks. First, the balance sheet is in at least decent shape. Here are three prudent steps to take. 2023 InvestorPlace Media, LLC. And while Ocugen will need more capital at some point, the company at least has time to push OCU300 forward and get its story out to investors. The biotech stock promptly crashed by more than 30%. 7 Penny Stocks Poised for Explosive Growth in 2023, With No Revenue or Approved Treatments, Ocugen Stock Is a Clear Sell. The Ocugen 52-week low stock price is 0.93, which is 1.1% below the current share price. That doesnt mean success is guaranteed. The stock had gained some traction after they announced the Ocugen merger in April. The average price target among the five analysts covering the stock is $6, suggesting 27.9% downside from current levels. CanSinoBio will receive some of the profits, but Ocugen still would skyrocket with FDA approval and ensuing revenue and there are more products in the pipeline. The company has a gene therapy platform as well as two preclinical compounds that aim to treat retinal diseases. All rights reserved. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. It means that raising capital will be more difficult going forward. The Motley Fool has no position in any of the stocks mentioned. According to the prospectus, the combined company posted an operating loss of roughly $30 million in 2018. The Ocugen 52-week high stock price is 4.03, which is 328.7% above the current share price. If you missed that action, you missed all the gains. The statistics support having long-term exposure to this asset class. All rights reserved. Still, Ocugen investors who bought one year ago and held on have generated a huge return on their investment. We have provided a few examples below that you can copy and paste to your site: Your data export is now complete. The combined company has an agreement to sell the rights to NeoCart to privately held Medavate, leaving it reliant on Ocugens pipeline. Some of the names will rally big, putting together epic squeezes that can double or triple the stock prices in just a few days. Backlinks from other websites are the lifeblood of our site and a primary source of new traffic. Article printed from InvestorPlace Media, https://investorplace.com/2020/01/ocugen-stock-faint-heart/. Ocugens Big Run: One company that has been a home-run investment in the last year has been biotech stock Ocugen Inc (NASDAQ:OCGN). Matt McCall and the InvestorPlace Research Staff, statistics support having long-term exposure, Click here to see what Matt has up his sleeve now, There Are So Many Stocks to Buy Ocugen Isnt One of Them. Like Pfizer's BNT162b2 and Moderna's mRNA-1273, it requires two doses. Objective investors could have clearly seen then that there actually were significant reasons to be concerned. Sign up below to get this incredible offer! Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. And its at least possible that OCGN could wind up being a winner. Invest better with The Motley Fool. The Motley Fool has a disclosure policy. You canfollow Will on Twitterat @HealyWriting. Ocugen Inc. stock rises Wednesday, outperforms market Feb. 22, 2023 at 5:14 p.m. Written by 1125 N. Charles St, Baltimore, MD 21201. Ocugen had to go an unusual route to go public. What Is the Best EV Stock to Buy Now? Part of the proceeds will be used to support its partnership with Bharat. The company has no revenue, runs an annual deficit, and does not generate positive free cash flow. The latest closing stock price for Ocugen as of March 03, 2023 is. All rights reserved. Stock Price Forecast The 6 analysts offering 12-month price forecasts for Ocugen Inc have a median target of 4.75, with a high estimate of 8.00 and a low estimate of 3.00. Theres even room for more lines. Under the terms of the agreement, Ocugen is entitled to 45% of the profits from the commercialization of Covaxin in the U.S. and Canada. Cassava Sciences (NASDAQ:SAVA) has soared 454% in just the last three months. Nano-cap biotech play Ocugen has an intriguing story and a ton of risk. Until July 20, when OCGN stock jumped about 20%, shares were down 21% from the March low. A $30 million market capitalization doesnt mean Ocugen has no chance. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. If you use our chart images on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. Nasdaq The chances of anything more are small but the rewards could be huge. In the late summer of 2018, the stock crashed below $1 per share as investors sold off following a failed phase three trial. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The next key catalyst for the biotech stock could be the announcement of the details of the plan to win EUA for Covaxin in the U.S. market. The vaccine reportedly has a 78% efficacy rate against COVID-19, significantly lower than leading vaccines granted FDA emergency authorization. In fact, the SPDR S&P 500 (NYSE:SPY) total return over the last 12 months is 34.2%. Importantly, neither Bharat nor Indian regulators revealed the efficacy of the vaccine. But there is no question some big-name stocks performed better than others along the way. The Motley Fool has a disclosure policy. Add in a $31 million market capitalization and potentially significant cash burn, and Ocugen stock self-evidently is not for risk-averse investors. The short answer is: everything. Biotech companies have emerged from similar levels to become huge winners, as evidenced simply by looking at some of the best biotech stocks for 2019. The Ocugen deal is a way to salvage some limited value. If OCU300 is approved, theres a reasonably large market. Learn More. Another alternative is to sell some or all of your Ocugen stock and invest the money elsewhere. The huge gain came after the company's partner, Bharat Biotech, received emergency use authorization (EUA) in India for COVID-19 vaccine Covaxin. Probably the most important thing to do after Ocugen's crash, though, is to identify lessons learned and apply them to future investing decisions. Guys, theres no revenue here! Conditions only seem to get worse for Ocugen (NASDAQ:OCGN). Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. However, I wont be around to find out. Shares declined 85% in three sessions around the closing of the merger, which also included a 1-for-60 reverse stock split. Don't overlook another approach, especially if you're still sitting on a nice gain even after last week's major sell-off. Maybe. For now, though, what happens in India stays in India. But realizing value in practice usually is a difficult endeavor. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. One thing seems certain, however:Ocugens fate as an investment is closely tied to the ultimate outcome of Covaxin. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. *Stock Advisor returns as of June 7, 2021. Copyright Keith Speights has no position in any of the stocks mentioned. Nasdaq But it does mean something. A bout of buying in late July sent shares from 20 cents apiece to above 90 cents a share a few days. These options will be cheaper than owning the stock itself. Ocugen In 2021, Beyond: Optimism about Covaxin coupled with massive short squeezes in a handful of popular social media stocks sent Ocugen shares skyrocketing up to as high as $18.77 in February 2021. Klicken Sie auf Alle ablehnen, wenn Sie nicht mchten, dass wir und unsere Partner Cookies und personenbezogene Daten fr diese zustzlichen Zwecke verwenden. Hence, instead of ruining just two lives, this new Ocugen may be destroying the investment future of all who buy. A partnership with a respected Asian biotechnology company offers some validation to the pipeline, and a key product is progressing through Phase III trials. Ocugen does have at least 180 days to cure that problem, but the simplest answer is for the company to execute a reverse stock split. Most biotech companies have intriguing stories on paper; Ocugen is no different. Our 3 Top Picks. See disclosure here. You never know when they will suddenly go on a squeeze. Its top officers have experience at Pfizer (NYSE:PFE) and other well-respected pharmaceutical and biotechnology companies. Axsome Therapeutics (NASDAQ:AXSM) had an equity value below $75 million in March 2017; its now worth over $3 billion after rising over 1,000% last year. With $3.2 million in cash vs. current liabilities of $3.3 million, Ocugen likely has enough cash on hand to cover its short-term obligations. Shares of Ocugen (OCGN 4.03%) were crashing 19.2% lower as of 11:23 a.m. Admittedly one could argue that it could have been bought for a quarter and sold for 75 cents, but hindsight is 20/20 in all of these names. The second is that the balance sheet still needs some help. Investors need to understand the risk profile here. Article printed from InvestorPlace Media, https://investorplace.com/2019/12/no-pathway-forward-for-ocugen-stock/. Keith Speights has no position in any of the stocks mentioned. Ocugen Chairman and CEO Shankar Musunuri Ocugen The company's stock opened at $8.24 per share Tuesday, up 96 cents. Conditions have only become worse since that time. On June 10, though, Ocugen announced that the U.S. Food and Drug Administration (FDA) had effectively shut the door on an EUA filing. Create your Watchlist to save your favorite quotes on Nasdaq.com. These symbols will be available throughout the site during your session. Sie knnen Ihre Einstellungen jederzeit ndern, indem Sie auf unseren Websites und Apps auf den Link Datenschutz-Dashboard klicken. MALVERN, Pa., May 29, 2018 /PRNewswire/ -- Ocugen, Inc., a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular diseases, today announced that it will present at the 2018 BIO International Convention, taking place June 4-7, 2018, in Boston. It has no treatments to offer the market. Just a few days ago, Ocugen (NASDAQ: OCGN) was flying high with shares up more than 460% year to date. Shares fell 72% on the news, and kept falling after Histogenics decided to suspend development of the product in December 2018. Keith Speights for Bharat Biotech has a history of successful vaccine commercialization in South Asia. Ocugen Inc Stock - OCGN Share Price Today, News and Discussion 0.90% SPY 0.59% QQQ 0.60% TSLA 6.12% SI 60.35% CRM 11.51% RIVN 0.32% ARKK 0.96% RLY.X 56.44% PLUG 6.72% V 0.22% CDIO 13.87% RETA 5.92% More Advertisement 3rd Party Ad. You can be a growth investor, futures trader, deep-value investor, a day trader, options player, or a dividend aficionado. Ocugen, previously a private company, instituted a reverse merger, which they completed on Sep. 30. Weitere Informationen ber die Verwendung Ihrer personenbezogenen Daten finden Sie in unserer Datenschutzerklrung und unserer Cookie-Richtlinie. The huge gain came after the company's partner, Bharat Biotech, received emergency use authorization. Instead of buying a piece of the S&P 500 or Nasdaq or even better, a common sense mega-holding like Apple (NASDAQ:AAPL) or Amazon investors in OCGN stock took on a high-risk investment and for months saw negative returns. quotes delayed at least 15 minutes, all others at least 20 minutes. All rights reserved. Investors were hopeful that the small drugmaker would be able to win U.S. Bei der Nutzung unserer Websites und Apps verwenden wir, unsere Websites und Apps fr Sie bereitzustellen, Nutzer zu authentifizieren, Sicherheitsmanahmen anzuwenden und Spam und Missbrauch zu verhindern, und, Ihre Nutzung unserer Websites und Apps zu messen, personalisierte Werbung und Inhalte auf der Grundlage von Interessenprofilen anzuzeigen, die Effektivitt von personalisierten Anzeigen und Inhalten zu messen, sowie, unsere Produkte und Dienstleistungen zu entwickeln und zu verbessern. The all-time high Ocugen stock closing price was, The average Ocugen stock price for the last 52 weeks is. In this case, shares rallied about four-fold in just a few days. Wenn Sie Ihre Auswahl anpassen mchten, klicken Sie auf Datenschutzeinstellungen verwalten. Ocugen executives even sounded cautiously optimistic in the company's fourth-quarter conference call last month. The simplest thing to do is to hang onto the stock and hope that it recovers sooner or later (which is a possibility). The $25 million private placement executed before the merger brought in much-needed cash. Ocugen stated in a press release that it plans to "continue working with the FDA to evaluate the regulatory pathway for the pediatric use of Covaxin." The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The point is, the risk/reward of owning something like Ocugen is simply not worth it vs. having even basic equity exposure. CanSinoBio will be able to fund much of the development of OCU300, Ocugens flagship product that targets oGVHD (ocular graft versus host disease), a common complication of bone marrow transplants. COVID-19 vaccines from Pfizer and Moderna are already on the market in the U.S. with efficacy levels of 94% or greater. To find good ideas for coronavirus stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights. Those reverse splits generally are poorly received by the market, even if in theory they should have little to no practical impact on trading. In other words, it means that even by biotech standards OCGN stock is an enormously risky play. More importantly, the 5-star analyst added, COVAXIN also induces comparable levels of neutralizing antibodies to those in human convalescent serum," which, the analyst believes," bodes well for the success of the ongoing Phase 3 trial in India.. The reverse merger with Histogenics was a disappointment, but the purchase price for the NeoCart intellectual property suggests that company had little chance of survival on its own. That's right -- they think these 10 stocks are even better buys. The worst news was that another late-stage clinical study will likely be required to support the regulatory filing. Indeed, the price broke below the 24 December 2018 low at 4.81 and is currently attempting a return move. Accordingly, the analyst rates OCGN a Neutral (i.e. Almost all the headlines about Ocugen in the past year have been about the companys COVID-19 vaccine candidate. With this, the newly formed Ocugen initiated a 60:1 reverse stock split. However, an EUA in India doesn't mean that Covaxin is a slam dunk to win EUA in the U.S., as well. Still, Ocugens balance sheet isnt as dire as its share price might suggest. *Average returns of all recommendations since inception. Some investors had set their hopes on the FDA being more lenient with pediatric use of Covaxin. The content is intended to be used for informational purposes only. It's hard to say for sure. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2023, Nasdaq, Inc. All Rights Reserved. The S&P 500 has rallied 52.9% from the March low to its highs on August 6. The equity has experienced a continual decline for years. Honestly, OCGN stock is unlikely to survive. Looking ahead, analysts are skeptical Covaxin will provide the upside Ocugen bulls are expecting. Unfortunately, both the merger and the reverse split have failed to stem the decline of former Histogenics stock. Some were undoubtedly anticipating a relatively quick EUA win for Covaxin followed by strong U.S. sales for the COVID-19 vaccine. OCU300 already has received an orphan drug designation from the U.S. Food & Drug Administration for oGVHD; there is no currently approved treatment in the U.S. The reverse merger that brought Ocugen to the public markets led to huge losses but some investors are buying the dip. David and Tom just revealed what they believe are the ten best stocks for investors to buy right now and Ocugen, Inc. wasn't one of them! After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. Its certainly possible the deal will fall through, leaving Ocugen with just the $15.8 million in cash with which it closed the third quarter, according to its 10-Q. But theres a big difference in having an edge flipping sub-$5 stocks vs. combing over this group as an investor looking for sound fundamentals and a mistakenly low stock price. It has real products. The steep decline came after the company announced that the U.S. Food and Drug Administration (FDA) won't grant Emergency Use Authorization (EUA) for COVID-19 vaccine Covaxin in children ages two to 18. Even though Ocugen did raise $25 million in a private placement, the story behind OCU300 clearly was not enough to support an initial public offering on its own. 10 stocks we like better than Ocugen, Inc.When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. When the market crashed during the U.S. pandemic outbreak in March, shares of vaccine makers understandably soared as work began on developing vaccines to fight COVID-19. Ocugen Inc First Quarter 2022 Financial Results and Recent Business Highlights 04/21/2022 Noble Capital Markets' Eighteenth Annual Investor Conference 03/14/2022 34th Annual ROTH Conference 02/25/2022 Ocugen, Inc. Q4 and Full Year 2021 Financial Results and Recent Business Highlights 01/10/2022 H.C. Wainwright Bioconnect Conference 12/22/2021 Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. With no effective treatments, and without a clear reason to exist, I would avoid buying Ocugen stock even as a speculative play. It is focused on discovering, developing and commercializing therapies which address rare and underserved eye diseases. Copyright 2023 InvestorPlace Media, LLC. Theres an opportunity here. Considering the conditions facing the company, I do not recommend Ocugen stock regardless of risk tolerances. Buy These 2 Stocks in 2023 and Hold for the Next Decade, 2 Stocks That Are About to Make Their Shareholders Richer, Join Over Half a Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, the company's fourth-quarter conference call last month, Copyright, Trademark and Patent Information. Investors should definitely reevaluate Ocugen's prospects in light of the company's bad news announced last week. Lorem ipsum dolor sit amet, consectetur adipiscing elit. The stock had gained some traction after they announced the. So, what goes wrong? If they invent a miracle treatment for a condition, the money will find its way to the stock. David and Tom just revealed what they believe are the ten best stocks for investors to buy right now and Ocugen, Inc. wasn't one of them! Other than an emphasis on cell therapies, the companies had almost nothing in common. So far, that merger hasnt worked out for Histogenics former shareholders. Related Link: If You Invested $1,000 In Moderna Stock One Year Ago, Here's How Much You'd Have Now. ET on Friday. Even at around 40 cents per share, I would consider Ocugen stock overvalued. Making the world smarter, happier, and richer. The sale of NeoCart, which still is pending, can bring in another $8 million, based on the current agreement. For now, the biggest near-term hope for Covaxin may be that Canada or another developed economy will buy the vaccine to share with developing nations. If it goes down, your loss won't be as great as it would be if you held onto all of your shares. Unfortunately, when the market bounced in late March 2020, Ocugen kept heading lower. Generally, financial analysts struggle with this sector because these equities rise and fall not on revenue or earnings, but the success of clinical trials. If they have solid financials, but their trials continually fail, they will likely not succeed. The market capitalization of Relmada Therapeutics (NASDAQ:RLMD) went from under $10 million at the end of 2017 to over $500 million at the moment. The odds of Ocugen stock winding up at zero are material. In November, Bharat Biotech began Phase 3 testing of Covaxin in India. 7 Penny Stocks Poised for Explosive Growth in 2023, Ocugen Stock Is Not for the Faint of Heart. Histogenics itself highlights the risks involved in small-cap biotech. Thats one of the best rallies weve seen in that amount of time (95 trading sessions, 136 days). Maybe it pans out for Ocugen and I wish the team (and its investors) the best of luck. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. Why Ocugen Stock Is Crashing Today By Keith Speights - Mar 4, 2022 at 11:42AM Key Points The FDA gave a thumbs-down to Ocugen's EUA request for the pediatric use of Covaxin. For example, after the FDA revised its guidelines for the EUA process for COVID-19 vaccines, Ocugen's CEO stated, "Since we have been in discussions with the FDA since late last year, we do not believe that the FDA's recently revised guidance regarding EUAs raises any concerns about our ability to submit the EUA for Covaxin as planned." However, when that occurred, Ocugen stock lost most of its value. Still, Ocugen investors who bought one year ago and held on have generated a huge return on their. Thats the thing with these low-priced penny stocks. Ocugen announced in late Decemberit had signed a letter of intent to co-develop COVID-19 vaccine candidate Covaxin along with Indian pharmaceutical company Bharat Biotech. Ocugen came to the market via what was essentially a reverse merger with Histogenics Corporation, a deal that closed at the end of September. The post There Are So Many Stocks to Buy Ocugen Isnt One of Them appeared first on InvestorPlace. However, the marriage of Histogenics and Ocugen looks destined to end in a suicide pact instead of a mere divorce. Please check your download folder. 1125 N. Charles St, Baltimore, MD 21201. The FDA typically takes 60 days to accept a regulatory filing then 10 months to make an approval decision. Will Be Even Bigger Than Your Wildest Expectation, 7 Over-$100 Stocks That Are Worth Every Penny, Louis Navellier and the InvestorPlace Research Staff, 5 Penny Cryptos With the Most Potential for Growth. Ocugen has responded to Health Canada regarding deficiencies identified with its regulatory filing for Covaxin. InvestorPlace - Stock Market News, Stock Advice & Trading Tips. If Ocugen goes up, you can still profit. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. Ocugen isnt a promotional, fly-by-night penny stock. Theres even room for more lines. That said, for investors who understand the potential downside, there is an intriguing story here. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Shares of Ocugen (OCGN) skyrocketed over 800% in the past three trading sessions after the biopharmaceutical company disclosed it had signed a binding letter of intent (LOI) with India based Bharat Biotech to co-develop a COVID-19 vaccine for the U.S. market.
11 Dpo Symptoms Disappeared,
Jeffrey Azoff Wedding,
Craigslist Sacramento Cars By Dealer,
10 Reasons Why Private Schools Are Bad,
Jeffrey Goldberg Msnbc,
Articles O
